Assessment of serum inflammatory parameters in RRMS and SPMS patients.

IF 1.7 4区医学 Q3 CLINICAL NEUROLOGY

Neurological Research Pub Date : 2024-06-01 Epub Date: 2024-05-02 DOI:10.1080/01616412.2024.2337503

Maria Nowak-Kiczmer, Natalia Niedziela, Zenon P Czuba, Paweł Sowa, Krzysztof Wierzbicki, Michał Lubczyński, Monika Adamczyk-Sowa

{"title":"Assessment of serum inflammatory parameters in RRMS and SPMS patients.","authors":"Maria Nowak-Kiczmer, Natalia Niedziela, Zenon P Czuba, Paweł Sowa, Krzysztof Wierzbicki, Michał Lubczyński, Monika Adamczyk-Sowa","doi":"10.1080/01616412.2024.2337503","DOIUrl":null,"url":null,"abstract":"Objectives: Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease. Patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) differ in their responses to treatment; therefore, the correct diagnosis of the particular type of MS is crucial, and biomarkers that can differentiate between the forms of MS need to be identified. The aim of this study was to compare the levels of inflammatory parameters in serum samples from patients with RRMS and SPMS.Methods: The study group consisted of 60 patients with diagnosed MS. The patients were divided into RRMS and SPMS groups. In the RRMS patients, the usage of disease-modifying treatment was included in our analysis. The serum levels of inflammatory parameters were evaluated.Results: The serum levels of BAFF, gp130 and osteopontin were significantly higher in SPMS patients than in RRMS patients. The serum levels of BAFF correlated with age in both RRMS and SPMS patients. The serum levels of MMP-2 were significantly higher in RRMS patients than in SPMS patients and correlated with the number of past relapses. The serum levels of IL-32 were significantly higher in RRMS treatment-naïve patients than in RRMS patients treated with disease-modifying therapy.Discussion: Significant differences were found in BAFF, gp130, MMP-2 and osteopontin levels between RRMS and SPMS patients. Serum IL-32 levels were statistically lower in RRMS patients treated with disease-modifying therapy than in treatment-naïve patients.","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"495-504"},"PeriodicalIF":1.7000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01616412.2024.2337503","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease. Patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) differ in their responses to treatment; therefore, the correct diagnosis of the particular type of MS is crucial, and biomarkers that can differentiate between the forms of MS need to be identified. The aim of this study was to compare the levels of inflammatory parameters in serum samples from patients with RRMS and SPMS.

Methods: The study group consisted of 60 patients with diagnosed MS. The patients were divided into RRMS and SPMS groups. In the RRMS patients, the usage of disease-modifying treatment was included in our analysis. The serum levels of inflammatory parameters were evaluated.

Results: The serum levels of BAFF, gp130 and osteopontin were significantly higher in SPMS patients than in RRMS patients. The serum levels of BAFF correlated with age in both RRMS and SPMS patients. The serum levels of MMP-2 were significantly higher in RRMS patients than in SPMS patients and correlated with the number of past relapses. The serum levels of IL-32 were significantly higher in RRMS treatment-naïve patients than in RRMS patients treated with disease-modifying therapy.

Discussion: Significant differences were found in BAFF, gp130, MMP-2 and osteopontin levels between RRMS and SPMS patients. Serum IL-32 levels were statistically lower in RRMS patients treated with disease-modifying therapy than in treatment-naïve patients.

查看原文本刊更多论文

RRMS 和 SPMS 患者的血清炎症指标评估。

目的：多发性硬化症（MS）是一种慢性自身免疫性炎症疾病。复发性缓解型多发性硬化症（RRMS）和继发性进展型多发性硬化症（SPMS）患者对治疗的反应各不相同；因此，正确诊断特定类型的多发性硬化症至关重要，而且需要确定能够区分不同类型多发性硬化症的生物标志物。本研究旨在比较 RRMS 和 SPMS 患者血清样本中的炎症参数水平：研究小组由 60 名确诊为多发性硬化症的患者组成。这些患者被分为 RRMS 组和 SPMS 组。在 RRMS 患者中，我们的分析包括是否使用了疾病修饰治疗。我们对血清中的炎症参数水平进行了评估：结果：SPMS患者血清中的BAFF、gp130和Osteopontin水平明显高于RRMS患者。RRMS 和 SPMS 患者血清中 BAFF 的水平与年龄相关。RRMS 患者血清中的 MMP-2 水平明显高于 SPMS 患者，且与既往复发次数相关。未经治疗的RRMS患者血清中IL-32水平明显高于接受疾病改变疗法治疗的RRMS患者：讨论：研究发现，RRMS和SPMS患者的BAFF、gp130、MMP-2和骨化蛋白水平存在显著差异。据统计，接受疾病修饰疗法治疗的RRMS患者血清IL-32水平低于治疗无效患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurological Research 医学-临床神经学

CiteScore

3.60

自引率

0.00%

发文量

116

审稿时长

5.3 months

期刊介绍： Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences. It provides a medium for those who recognize the wider implications of their work and who wish to be informed of the relevant experience of others in related and more distant fields. The scope of the journal includes: •Stem cell applications •Molecular neuroscience •Neuropharmacology •Neuroradiology •Neurochemistry •Biomathematical models •Endovascular neurosurgery •Innovation in neurosurgery.